GlassScriptPhysician profile
Richard Kim
NPI 1932181260
$9,373.53
in general payments reported to CMS, 2019-2025
36 companies · $1,659 in 2025
The $1,659 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,947 · 2020: $441 · 2021: $792 · 2022: $1,208 · 2023: $1,601 · 2024: $1,726 · 2025: $1,659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,929 · Education: $56.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,929.10 |
| Education | $56.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,174.14 | 2019-2025 | |
| Janssen Biotech, INC. | $997.54 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $694.87 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $661.86 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $614.85 | 2019-2025 | |
| Ardelyx, INC. | $484.46 | 2022-2025 | Ibsrela |
| Daiichi Sankyo INC. | $350.81 | 2019-2025 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $342.90 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $202.49 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $183.01 | 2019 | |
| Genzyme Corporation | $178.61 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $149.77 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $141.38 | 2023-2025 | Iqirvo, Bylvay |
| Organon LLC | $135.43 | 2021-2025 | Hadlima, Renflexis |
| Ironwood Pharmaceuticals, INC | $124.56 | 2019-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $118.41 | 2019-2024 | Dificid, Zinplava |
| E.R. Squibb & Sons, L.L.C. | $113.07 | 2021 | |
| Shionogi INC | $101.93 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $95.67 | 2019-2022 | |
| Braintree Laboratories, INC. | $54.65 | 2020-2022 | |
| Qol Medical, LLC | $45.87 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $44.62 | 2019-2023 | Rebyota |
| Ethicon US, LLC | $43.57 | 2022 | |
| Celgene Corporation | $40.34 | 2022-2023 | Zeposia |
| Fresenius Kabi USA, LLC | $38.68 | 2024 | Idacio |
| Celltrion USA INC. | $34.63 | 2024 | Zymfentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.82 | 2024 | Cyltezo |
| Amgen INC. | $30.92 | 2023 | Avsola, Amjevita |
| Madrigal Pharmaceuticals | $28.17 | 2025 | Rezdiffra |
| Ucb, INC. | $23.38 | 2019 | |
| Redhill Biopharma INC. | $17.94 | 2020 | |
| Shire North American Group INC | $17.93 | 2019 | |
| Evoke Pharma, INC. | $15.60 | 2024 | |
| Aimmune Therapeutics, INC. | $14.70 | 2025 | Vowst |
| Lilly USA, LLC | $13.27 | 2023 | |
| Allergan, INC. | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.